Novo Aims to Beat Lilly With Something for Everyone in Obesity

Novo Nordisk A/S is working on a strategy to make obesity treatment more personalized and wants to offer options for every kind of patient.

The Danish company envisions a trajectory of treatment that could change for different patient groups, said Ludovic Helfgott, Novo’s new chief of product and portfolio strategy. The approach is still being developed and will harness new versions of Novo’s blockbuster weight-loss medicine Wegovy, he said, including a pill that the drugmaker hopes to start selling in the US early next year.